Nitinol stent implantation in long superficial femoral artery lesions: 12-Month results of the DURABILITY I study

Journal of Endovascular Therapy

Volumn 16, Issue 3, 2009, Pages 261-269

  Bosiers, Marc ^a   Torsello, Giovanni ^b   Gißler, Hans Martin ^a   Ruef, Johannes ^c   Müller Hülsbeck, Stefan ^d   Jahnke, Thomas ^d   Peeters, Patrick ^e   Daenens, Kim ^f   Lammer, Johannes ^g   Schroë, Herman ^h   Mathias, Klaus ⁱ   Koppensteiner, Renate ^g   Vermassen, Frank ^j   Scheinert, Dierk ^k  

^a AZ St Blasius ^*  (Germany)

^b ST FRANZISKUS HOSPITAL   (Germany)

^c Red Cross Hospital Cardiology Center   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e IMELDA HOSPITAL   (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF VIENNA   (Austria)

^h DEPARTMENT OF CARDIOLOGY   (Belgium)

ⁱ KLINIKUM DORTMUND   (Germany)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

^k Park Krankenhaus   (Germany)

more..

Author keywords

Occlusions; Outcome analysis; Peripheral artery disease; Restenosis; Stenosis; Stent fracture; Superficial femoral artery

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; NITINOL; TICLOPIDINE; WARFARIN;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTENOSIS; REVASCULARIZATION; RUTHERFORD CLASSIFICATION; STENT; SUPERFICIAL FEMORAL ARTERY;

ADULT; AGED; AGED, 80 AND OVER; ALLOYS; ANGIOPLASTY, BALLOON; ATHEROSCLEROSIS; EQUIPMENT DESIGN; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 68549090697     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1583/08-2676.1     Document Type: Article

References (12)

1. White GH, Liew SC, Waugh RC, et al. Early outcome and intermediate follow-up of vascular stents in the femoral and popliteal arteries without long-term anticoagulation. J Vasc Surg. 1995;21:270-281.
2. Henry M, Amor M, Beyar R, et al. Clinical experience with a new nitinol self-expanding stent in peripheral arteries. J Endovasc Surg. 1996;3:369-379. (Pubitemid 26411946)
3. Gray BH, Sullivan TM, Childs MB, et al. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg. 1997;25:74-83.
4. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31(1 Pt 2):S1-S296.
5. Norgren L, Hiatt WR, Dormandy JA, et al. InterSociety Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75. (Pubitemid 46068992)
6. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-1888. (Pubitemid 43872689)
7. Sabeti S, Mlekusch W, Amighi J, et al. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther. 2005;12:6-12. (Pubitemid 40229383)
8. Krankenberg H, Schluter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116:285-292. (Pubitemid 47196564)
9. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312-315. (Pubitemid 40094743)
10. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701-710. (Pubitemid 44907633)
11. Katzen B. The Resilient Trial 12-Month Analysis. Presented at: Transcatheter Cardiovascular Therapeutics. Washington DC; October 23, 2007.
12. LifeStent FlexStar and FlexStar XL Summary of safety and effectiveness data. Available at: http://www.accessdata.fda.gov/cdrh-docs/pdf7/P070014b.pdf. Accessed March 12, 2009.